Literature DB >> 14740638

Cancer pharmacogenetics: polymorphisms, pathways and beyond.

Cornelia M Ulrich1, Kim Robien, Howard L McLeod.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14740638     DOI： 10.1038/nrc1233

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  54 in total

Review 1.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.

Authors:  Barbara Pardini; Rajiv Kumar; Alessio Naccarati; Jan Novotny; Rashmi B Prasad; Asta Forsti; Kari Hemminki; Pavel Vodicka; Justo Lorenzo Bermejo
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 3.  Gender specific tumour pharmacology--from kinetics to genetics.

Authors:  Robert M Mader
Journal:  Wien Med Wochenschr       Date:  2006-10

4.  ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.

Authors:  Ute Warnecke-Eberz; Daniel Vallböhmer; Hakan Alakus; Fabian Kütting; Georg Lurje; Elfriede Bollschweiler; Anke Wienand-Dorweiler; Uta Drebber; Arnulf H Hölscher; Ralf Metzger
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

Review 5.  Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients.

Authors:  Wataru Ichikawa; Yasutsuna Sasaki
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

6.  Functional polymorphisms of circadian negative feedback regulation genes are associated with clinical outcome in hepatocellular carcinoma patients receiving radical resection.

Authors:  Zhaohui Zhang; Fei Ma; Feng Zhou; Yibing Chen; Xiaoyan Wang; Hongxin Zhang; Yong Zhu; Jianwei Bi; Yiguan Zhang
Journal:  Med Oncol       Date:  2014-10-26       Impact factor: 3.064

Review 7.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

8.  Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.

Authors:  Pierre Bohanes; Cathryn J Rankin; Charles D Blanke; Thomas Winder; Cornelia M Ulrich; Stephen R Smalley; Tyvin A Rich; James A Martensen; Al B Benson; Robert J Mayer; Christine M Cripps; Kathleen Danenberg; Karen W Makar; Wu Zhang; Jacqueline K Benedetti; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

9.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

10.  Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer.

Authors:  Fei Fei; Xu Guo; Yibing Chen; Xiaonan Liu; Jianfei Tu; Jinliang Xing; Zhinan Chen; Jiansong Ji; Xianli He
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-10       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.